Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117949 · ClinicalTrials.gov registry record · Phase 2
Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT00117949 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 82 participants.
The verdict
NCT00117949, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
Population pharmacokinetic and pharmacodynamic data from Study FE200486 CS06 and FE200486 CS02 provided further knowledge of the optimal dose regimens for FE200486 (degarelix). Both studies were to guide dose selection for phase III. In addition, safety and tolerance data were generated.
Interventions
- DRUG Degarelix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2002-04 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00117949
The ClinicalTrials.gov registry entry for NCT00117949 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Degarelix is the first listed.
NCT00117949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00117949 about?
NCT00117949 is a clinical study titled "Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486". Population pharmacokinetic and pharmacodynamic data from Study FE200486 CS06 and FE200486 CS02 provided further knowledge of the optimal dose regimens for FE200486 (degarelix). Both studies were to guide dose selection for phase III. In addition, safety and tolerance data were generated.
What is the current status of trial NCT00117949?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2002-04. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00117949?
The interventions under investigation include: Degarelix (DRUG).
Who is sponsoring clinical trial NCT00117949?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.